Yeah thats right don't do itThe way I see it Wooley will have to raise the bid if he wants control or management will end up selling the assets.Either way a win-win for us
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress